arrow
M

Małgorzata Pieniążek

Wroclaw Medical University
H指数:10
被引数:277

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction to: Primary G-CSF prophylaxis in sacituzumab govitecan–treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort

更正:沙西妥珠单抗 govitecan 治疗的 mTNBC 中的一级 G-CSF 预防:来自跨国 CEBCC-102 研究队列的真实世界证据

2026-11-050
OAAI
Association of PD-L1 combined positive score with disease control and response kinetics with first-line pembrolizumab-based therapy in metastatic triple-negative breast cancer: results from routine clinical practice in Poland

PD-L1联合阳性评分与一线帕博利珠单抗为基础疗法在转移性三阴性乳腺癌中的疾病控制及反应动力学的关系:波兰常规临床实践结果

2026-06-100
OAAI
Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort

接受sacituzumab govitecan治疗的转移性三阴性乳腺癌患者的联合阳性评分状态: 中欧队列中的相关临床特征和测试模式

2026-02-020
PRE
Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe
2026-01-240
OA
Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study

sacituzumab govitecan在预先治疗的三阴性乳腺癌和脑转移患者中的真实结果: 来自CEBCC-102研究的数据

2026-01-140
PRE
Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study

Sacituzumab govitecan在转移性化生性三阴性乳腺癌患者中的疗效与安全性:一项来自CEBCC-102研究的跨国回顾性病例系列研究

2025-12-090
OAAI
Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety

Sacituzumab Govitecan在波兰转移性三阴性乳腺癌患者中的初始剂量降低:对疗效和安全性的影响

2025-10-040
OA
Strategies for premedication and G-CSF application in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights

曲拉妥珠单抗(sacituzumab govitecan)治疗三阴性乳腺癌患者的预用药及粒细胞集落刺激因子(G-CSF)应用策略:多中心见解

2025-09-280
OA
Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis

基线血红蛋白和嗜中性粒细胞与淋巴细胞比值作为接受sacituzumab govitecan治疗的转移性三阴性乳腺癌患者(二线及以上治疗)的预后生物标志物:一项真实世界分析

2025-09-270
OA
Time from Final Oncologist Visit to Death and Palliative Systemic Treatment Use Near the End of Life in Heavily Pretreated Patients with Luminal Breast Cancer

在经过大量预处理的管腔乳腺癌患者中,从最终的肿瘤科医生就诊到死亡和姑息性全身治疗的时间接近生命的终点

2024-11-080
OAAI
Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study

Sacituzumab Govitecan用于三阴性乳腺癌患者的二线和后续姑息治疗: 一项波兰真实世界多中心队列研究

2024-09-270
OAAI